<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of resistant or recurrent gestational trophoblastic neoplasia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of resistant or recurrent gestational trophoblastic neoplasia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of resistant or recurrent gestational trophoblastic neoplasia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ross S Berkowitz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil S Horowitz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin M Elias, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H19650228"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term gestational trophoblastic neoplasia (GTN) is used when molar and nonmolar pregnancies become malignant. GTN comprises specific histologic entities, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Invasive mole</p><p class="bulletIndent1"><span class="glyph">●</span>Choriocarcinoma</p><p class="bulletIndent1"><span class="glyph">●</span>Placental site trophoblastic tumor (PSTT)</p><p class="bulletIndent1"><span class="glyph">●</span>Epithelioid trophoblastic tumor (ETT)</p><p></p><p>GTN is a rare disease that ideally should be managed at trophoblastic disease centers where concentration of cases provides clinicians with ample experience, opportunities for research, and improved outcomes [<a href="#rid1">1</a>]. Since most patients are managed locally, however, it is important for clinicians who encounter these patients to familiarize themselves with the latest advances in the field in order to optimize their patients' outcomes.</p><p>Prior to the development of effective chemotherapy for GTN, the majority of patients with disease localized to the uterus were cured with hysterectomy, whereas metastatic disease was almost uniformly fatal [<a href="#rid2">2</a>]. With the utilization of sensitive quantitative assays for human chorionic gonadotropin (hCG) and highly effective chemotherapy, most patients with GTN can be cured and their reproductive function preserved, providing they are managed according to well-established guidelines [<a href="#rid3">3,4</a>]. However, patients are at risk for both resistant and recurrent GTN, which will require further therapy. This is especially true if initial treatment is inappropriate [<a href="#rid5">5</a>]. Despite this, patients who experience a recurrence stand a good chance of achieving remission.</p><p>Patients whose hCG level re-elevates after becoming undetectable are considered to have recurrent disease. By contrast, patients whose hCG level remains elevated despite treatment are considered to have resistant disease.</p><p>This topic will discuss the approach to and treatment of resistant or recurrent GTN. The pathology, epidemiology, clinical manifestations, diagnosis, and management of hydatidiform mole and low-risk and high-risk GTN are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3230.html" rel="external">"Gestational trophoblastic disease: Pathology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3243.html" rel="external">"Hydatidiform mole: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3194.html" rel="external">"Hydatidiform mole: Treatment and follow-up"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3209.html" rel="external">"Human chorionic gonadotropin: Biochemistry and measurement in pregnancy and disease"</a>.)</p><p></p><p class="headingAnchor" id="H19650234"><span class="h1">ESTIMATING THE RISK OF RESISTANT OR RECURRENT DISEASE</span><span class="headingEndMark"> — </span>Patients treated for GTN are at varying risks of developing either resistant or recurrent disease. In one study, the reported recurrence rates according to International Federation of Gynecology and Obstetrics (FIGO) staging  (<a class="graphic graphic_table graphicRef98185" href="/d/graphic/98185.html" rel="external">table 1</a>) were as follows [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage I (non-metastatic) – 2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stages II and III; low-risk GTN – 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage II to IV; high-risk – 13 percent</p><p></p><p>At the New England Trophoblastic Disease Center, the reported recurrence rates were 2.9 percent in patients with non-metastatic disease, 8.3 percent in stage II patients, 4.2 percent in stage III patients, and 9.1 percent in patients with FIGO stage IV disease [<a href="#rid7">7</a>]. In a study of 1827 patients with GTN from Peking Union Medical College in Beijing, recurrence was associated with an interval between the antecedent pregnancy and chemotherapy &gt;12 months, and an interval from first chemotherapy to achieving β-human chorionic gonadotropin (hCG) normalization &gt;14 weeks [<a href="#rid8">8</a>].</p><p>An increasing total FIGO risk score correlates with a corresponding increase in the likelihood of chemotherapy resistance. However, the majority of the risk factors reflect large initial tumor burden (eg, higher hCG, tumor size, presence and number of metastases), and are not independent prognostic factors [<a href="#rid9">9</a>]. Inadequate primary therapy and noncompliance or loss to follow-up are also important risk factors for resistance [<a href="#rid5">5</a>]. Several studies have also noted that a low uterine artery pulsatility index, as assessed by Doppler ultrasound prior to chemotherapy initiation, is a marker for higher tumor vascularity and suggests an increased risk of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> resistance [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H19650240"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>All patients who develop chemoresistant or recurrent disease require re-staging. In addition, this evaluation should be repeated each time a new course of treatment is indicated. (See  <a class="medical medical_review" href="/d/html/95881.html" rel="external">"Gestational trophoblastic neoplasia: Epidemiology, clinical features, diagnosis, staging, and risk stratification", section on 'Staging and risk assessment'</a>.)</p><p>Patients who recur or develop resistance often have multiorgan involvement, particularly if they were previously treated for high-risk GTN [<a href="#rid12">12</a>]. Therefore, re-imaging with chest, abdominal, and pelvic computed tomography (CT) scans and brain magnetic resonance imaging (MRI) should be performed to help guide treatment options. For patients in whom the diagnosis is questionable, positron emission tomography (PET) scanning may aid in the differential characterization of active disease (which should be PET-positive) from fibrotic tumor nodules [<a href="#rid13">13-15</a>].</p><p class="headingAnchor" id="H19650246"><span class="h1">LOW-RISK GTN</span><span class="headingEndMark"> — </span>In general, primary resistance after single-agent chemotherapy occurs in 10 to 30 percent of patients with low-risk GTN. However, this figure rises to between 30 and 50 percent of patients with low-risk GTN in the presence of metastases. Patients who develop resistance to the initial single agent usually will respond to an alternative single agent, and only 5 to 10 percent will require multiagent therapy [<a href="#rid16">16,17</a>]. </p><p>There have been no randomized trials comparing single-agent with multiagent chemotherapy for patients with low-risk GTN who experience primary resistance to single-agent chemotherapy. However, our clinical experience indicates that a second-line single-agent therapy is effective and induces remission in the vast majority of patients. As such, this is our preferred approach. Other institutions, however, use human chorionic gonadotropin (hCG) level at the time of introduction of second-line treatment to determine whether single- or multiagent chemotherapy should be initiated. For patients with an hCG level under 1000 international units/L, single-agent actinomycin D (ActD) is their standard choice, while for patients with an hCG &gt;1000 international units/L at the time of treatment, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), ActD, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (EMA-CO) is chosen. Using this cutoff, approximately 93 percent of patients treated with single-agent ActD successfully completed treatment without requiring additional therapy [<a href="#rid18">18</a>]. Importantly, those who do not achieve remission are cured with additional therapy or surgery. By increasing the cut-off more patients were spared exposure to the more toxic EMA-CO regimen without compromising survival. Of note, some data suggest that patients with higher risk scores (ie, 5 to 6) are at a greater risk of resistant disease compared with those with lower prognostic scores. This was shown in one single-institution study in which only 30 percent of these patients went into a sustained remission with second-line monotherapy [<a href="#rid19">19</a>]. These patients characteristically present with a pretreatment hCG level &gt;100,000 milli-international units/mL and Doppler ultrasound evidence of a large tumor burden in their uterus [<a href="#rid19">19</a>]. For such patients, multiagent chemotherapy is a reasonable option.</p><p>In a multicenter retrospective, cohort study evaluating predictors of single-agent resistance (&gt;80 percent risk) in patients with FIGO score 5 or 6 GTN, about 60 percent of patients achieved remission with either first-line or second-line single agents [<a href="#rid20">20</a>]. Almost all patients without metastases or choriocarcinoma (CCA) attained remission with single agents, but 4 percent of these patients with hCG &gt;410,000 IU/L required combination chemotherapy. Among patients with either metastasis or CCA and hCG &gt;150,000 IU/L (14 percent of group), combination chemotherapy was required to attain remission, and all patients with metastatic CCA required combination chemotherapy.</p><p class="headingAnchor" id="H19650253"><span class="h2">Second-line single-agent chemotherapy</span><span class="headingEndMark"> — </span>For patients treated with MTX, with or without folinic acid (FA), who develop resistant or recurrent disease, we then administer biweekly bolus ActD. In our experience, more than 70 percent of these patients will achieve sustained remission with second-line ActD and avoid multiagent chemotherapy [<a href="#rid21">21-23</a>]. If the initial treatment was ActD, we proceed with treatment using MTX-FA. These and other single-agent options are discussed separately. (See  <a class="medical medical_review" href="/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia", section on 'Methotrexate as the preferred option'</a> and  <a class="medical medical_review" href="/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia", section on 'Alternatives including dactinomycin and other agents'</a>.)</p><p>In patients with MTX resistance, single-agent <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> has been utilized with mixed results in two studies [<a href="#rid24">24,25</a>]. Complete remission was achieved with carboplatin in 11 of 23 (48 percent) and 17 of 21 (81 percent) patients. Grade 3 or 4 hematologic toxicity was seen with granulocytopenia in 48 and 38 percent and thrombocytopenia in 43 and 29 percent. When available, ActD should be the preferred second-line agent in patients with MTX-resistant, low-risk GTN.</p><p>An alternative treatment option for patients with MTX-resistant disease is <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>. In a phase II, multicenter trial evaluating avelumab (10 mg/kg every two weeks) in 15 patients with MTX-resistant GTN, hCG normalization occurred in eight patients (53 percent) after nine cycles (median) of avelumab during the 25-month (median) follow-up period; no patients relapsed [<a href="#rid26">26</a>]. Subsequent cure for the remaining seven patients was achieved with ActD or combination chemotherapy. Toxicities were consistent both in nature and frequency with those typically seen with immunotherapy.</p><p class="headingAnchor" id="H19650259"><span class="h2">Progression after second-line single-agent therapy</span><span class="headingEndMark"> — </span>Patients who have resistant or recurrent disease despite second-line single-agent chemotherapy should be treated with combination chemotherapy. As in patients with high-risk GTN, our regimen of choice is EMA-CO. (See <a class="local">'Later-line therapy'</a> below and  <a class="medical medical_review" href="/d/html/96232.html" rel="external">"Initial management of high-risk gestational trophoblastic neoplasia"</a>.)</p><p>For patients who do not respond to initial combination chemotherapy, alternative regimens can be offered. However, other modalities, including surgery, may be reasonably pursued. (See <a class="local">'Later-line therapy'</a> below and <a class="local">'Surgery'</a> below.)</p><p class="headingAnchor" id="H19650265"><span class="h1">HIGH-RISK GTN</span><span class="headingEndMark"> — </span>Despite the success of primary therapy with <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), and actinomycin D (ActD) alternating with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (EMA-CO), roughly 30 to 40 percent of patients with high-risk metastatic GTN will have an incomplete response to first-line therapy or will relapse from remission and will need additional multiagent chemotherapy with or without other treatment modalities [<a href="#rid12">12,27-29</a>]. Risk factors for resistant or recurrent disease include the presence of multiple metastases to sites other than the lung and vagina, and inadequate first-line chemotherapy. (See  <a class="medical medical_review" href="/d/html/96232.html" rel="external">"Initial management of high-risk gestational trophoblastic neoplasia", section on 'EMA-CO'</a>.)</p><p class="headingAnchor" id="H19650271"><span class="h2">Second-line combination therapy</span><span class="headingEndMark"> — </span>Although there are no universally accepted evidence-based guidelines for second-line treatment for patients who develop resistant or recurrent disease on first-line multiagent chemotherapy, our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients previously treated with EMA-CO, we administer the multiagent chemotherapy combination consisting of EMA followed by <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (EMA-EP). (See  <a class="medical medical_review" href="/d/html/96232.html" rel="external">"Initial management of high-risk gestational trophoblastic neoplasia", section on 'Cisplatin-containing regimens'</a>.)</p><p></p><p class="bulletIndent1">Neutropenia may become an issue for patients receiving EMA-CO followed by EMA-EP, and in our clinical experience, prolonged neutropenia develops by the second or third cycle. Therefore, growth factor support (ie, <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a>) is usually required [<a href="#rid30">30</a>]. In addition to chemotherapy, these patients may benefit from surgical excision of localized, persistent tumor [<a href="#rid31">31-33</a>]. Further discussion of the role of surgery is covered below. (See <a class="local">'Surgery'</a> below.)</p><p></p><p class="bulletIndent1">In one report of 21 patients who had previously received EMA-CO, EMA-EP (alone or in combination with surgery) induced remission in 16 (76 percent) [<a href="#rid34">34</a>]. In a separate report that included 49 patients, the complete remission rate was 82 percent [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who were not treated with EMA-CO in the first-line setting should undergo treatment with this combination in the second-line setting. (See  <a class="medical medical_review" href="/d/html/96232.html" rel="external">"Initial management of high-risk gestational trophoblastic neoplasia", section on 'EMA-CO'</a>.)</p><p></p><p class="headingAnchor" id="H19650277"><span class="h1">LATER-LINE THERAPY</span><span class="headingEndMark"> — </span>For patients with resistant or recurrent disease despite two prior combination regimens, a number of alternative regimens can be administered. However, none of these regimens have been used in a sufficient number of patients to identify one as being the optimal choice.</p><p>It is important to re-stage patients prior to the initiation of a new regimen so that the extent of disease may be appropriately characterized and to evaluate for a potential role for surgical treatment. Case reports of patients treated with these later-line regimens do not indicate that one is preferred over another.</p><p class="headingAnchor" id="H1022664978"><span class="h2">Multiagent therapy</span></p><p class="headingAnchor" id="H19650283"><span class="h3">TE-TP</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a> and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> alternating weekly with paclitaxel and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (TE-TP) has had encouraging results in heavily pretreated patients. It appears to be well tolerated as well, though the experience remains quite limited.</p><p class="bulletIndent1"><span class="glyph">●</span>In one report of two patients, both had a complete remission to this regimen [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate series of 16 patients (including six previously treated with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>), 19 and 31 percent had a complete and partial remission, respectively [<a href="#rid36">36</a>].</p><p></p><p><a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">Etoposide</a> has been linked to an increased risk of secondary tumors such as leukemia, melanoma, colon cancer, and breast cancer [<a href="#rid37">37</a>]. However, a subsequent report from the same institution on a larger number of patients suggested that the risk of secondary tumors may be more limited than originally described [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H364981643"><span class="h3">PC</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> (PC) was shown in one prospective study of 65 patients to produce remissions in approximately 60 percent of patients at a median follow-up of 30 months and may be an appropriate option for those wishing to avoid the possible increased risk for secondary tumors associated with etoposide-containing regimens [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H19650290"><span class="h3">BEP</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (BEP) is an available regimen, widely used to treat germ cell tumors of the ovary and testicle.<sup> </sup>In one report of 16 patients with EMA-CO-resistant disease, 11 patients (69 percent) had a complete response, and nine (56 percent) survived [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H19650297"><span class="h3">ICE</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (ICE) is often administered to men with recurrent or chemorefractory testicular cancer. Its use in patients with recurrent or resistant GTN is limited. In one experience that included six patients, four had a complete remission, and three ultimately survived [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H19650304"><span class="h3">PVB</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> (PVB) has only been reported in small case series of patients with high-risk, drug-resistant GTN. The complete remission rates range from 18 to 62 percent [<a href="#rid40">40-42</a>].</p><p class="headingAnchor" id="H19650310"><span class="h3">FU plus ActD</span><span class="headingEndMark"> — </span>High-dose <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) in conjunction with actinomycin D (ActD) is commonly used in Asia, though the experience with this regimen is limited. For example, one series of 11 patients reported a complete remission rate of 82 percent [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H4800214"><span class="h3">FUDR</span><span class="headingEndMark"> — </span>In one series, <a class="drug drug_general" data-topicid="8942" href="/d/drug information/8942.html" rel="external">floxuridine</a> (FUDR) in combination with ActD, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="10303" href="/d/drug information/10303.html" rel="external">vindesine</a> was reported to induce remission in all 21 patients, all of whom had evidence of chemotherapy-resistant disease [<a href="#rid44">44</a>]. Floxuridine-based regimens have also been reported to be highly effective in placental site trophoblastic tumor (PSTT), which is relatively resistant to chemotherapy [<a href="#rid45">45,46</a>]. In one study of 37 patients with stage II to IV PSTT treated with floxuridine-based regimens, 34 (92 percent) had an initial complete response and seven (20.6 percent) patients relapsed [<a href="#rid46">46</a>]. FUDR with ActD, etoposide, and <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (FAEV) was administered to 91 patients with chemotherapy-resistant or relapsed GTN and 55 (60 percent) patients achieved a complete remission, 29 had no response, and 7 had intolerable toxicity [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H19650316"><span class="h2">Single-agent therapy</span><span class="headingEndMark"> — </span>Very limited data suggest that single-agent treatment may provide benefit in patients with previously treated recurrent, advanced, or metastatic GTN. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paclitaxel</strong> – Case reports indicate that <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> may be an active agent following prior treatment. However, the experience with single-agent paclitaxel therapy remains quite limited [<a href="#rid48">48,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Capecitabine</strong> – A case report indicates that <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> may also be active in the management of relapsed high-risk GTN [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pegylated liposomal doxorubicin</strong> – <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">Pegylated liposomal doxorubicin</a> was reported to induce complete remission in two patients with chemotherapy-resistant high-risk GTN with brain metastases and having received multiple prior lines of chemotherapy [<a href="#rid51">51</a>].</p><p></p><p class="headingAnchor" id="H2559502918"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>New investigational therapies for GTN include immune checkpoint inhibitors and molecularly targeted agents. The rationale for immunotherapy in this disease is histologic evidence that GTNs strongly express programmed cell death ligand 1 (PD-L1) [<a href="#rid52">52-54</a>].</p><p>Due to the rarity of these diseases, prospective clinical trials are difficult to pursue, however, particularly for recurrent disease. Hence, further evidence of potential new therapies comes from small case series. In one such report, investigators administered the immune checkpoint inhibitor <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to four patients with resistant GTN [<a href="#rid55">55</a>]. Three of the four patients in the case series had a complete response, and all were durable at 24, 15, and 5 months after stopping treatment. Of note, all patients had tumors with &gt;90 percent programmed cell death protein 1 (PD-1) expression. In addition, all three patients expressed tumor-infiltrating lymphocytes, which were not present in the patient who did not respond to treatment. Additional case reports have reported similar results [<a href="#rid56">56,57</a>].</p><p>These provocative data point to the potential role of immune checkpoint inhibitors for resistant GTN and warrant further evaluation.</p><p>Antiangiogenic agents may also be active in the treatment of drug-resistant GTN. A 36-year-old patient with metastatic choriocarcinoma refractory to multiple lines of combination chemotherapy including stem cell transplant achieved a durable complete remission after receiving an anti-endoglin monoclonal antibody and <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> [<a href="#rid58">58</a>]. She remains in complete remission off therapy for greater than four years.</p><p class="headingAnchor" id="H19650328"><span class="h1">SURGERY</span><span class="headingEndMark"> — </span>For patients with recurrent or resistant GTN, a surgical approach may be curative. However, decisions regarding surgery must be individualized based upon the clinical scenario. The efficacy, feasibility, and type of surgery vary depending upon the site and extent of metastases.</p><p class="headingAnchor" id="H19650334"><span class="h2">Uterine disease</span><span class="headingEndMark"> — </span>Hysterectomy should be avoided if possible, especially for patients who desire future childbearing. However, it may be indicated after chemotherapy, especially for heavy bleeding, large bulky intrauterine disease, or in the presence of sepsis [<a href="#rid59">59</a>].<sup> </sup>In one report including 134 patients with GTN, a hysterectomy was performed in 13 (9 percent) patients for profuse bleeding and 31 (24 percent) for uterine perforation, respectively [<a href="#rid60">60</a>].</p><p>Hysterectomy may also be performed to manage chemotherapy resistance to reduce tumor burden [<a href="#rid61">61</a>]. At our center, hysterectomy was performed in 19 patients for drug resistance, and 16 (84 percent) of the patients attained a complete and sustained remission [<a href="#rid62">62</a>]. Similarly in another study, hysterectomy was performed in 18 patients with chemotherapy-resistant uterine tumors and 15 (83 percent) patients achieved complete remission [<a href="#rid63">63</a>].</p><p>For patients undergoing a hysterectomy, it is important to note that the removal of the ovaries is usually not indicated, even in the presence of theca lutein cysts. In our experience, metastatic disease involving the ovary is rare. Symptomatic ovarian theca lutein cysts can be aspirated if indicated, but otherwise will regress spontaneously after treatment.</p><p>Patients with GTN undergoing minimally invasive compared with open hysterectomy appear to have similar oncologic outcomes [<a href="#rid64">64</a>]. However, hospital length of stay and blood loss are less with minimally invasive approaches.</p><p class="headingAnchor" id="H19650341"><span class="h2">Bowel, splenic, and renal metastases</span><span class="headingEndMark"> — </span>Intra-abdominal metastases may require resection, as they are often less chemosensitive and may persist despite chemotherapy [<a href="#rid65">65,66</a>]. In addition, these metastases may cause complications, particularly hemorrhage<strong><sup> </sup></strong>[<a href="#rid65">65,67,68</a>]. Some data suggest that clinical parameters may predict the outcome following resection:</p><p class="bulletIndent1"><span class="glyph">●</span>In one series of 33 patients who underwent various surgical procedures for resistant or recurrent GTN, successful outcome was achieved mostly in patients with the following characteristics: a single preoperative disease site, underwent salvage surgery within one year of initial diagnosis, non-choriocarcinoma histology, and/or a total World Health Organization (WHO) score of &lt;8 [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report of 61 patients with chemoresistant GTN undergoing surgical salvage, the clinical factors that predicted failure were age over 35, human chorionic gonadotropin (hCG) &gt;10,000 milli-international units/mL, antecedent nonmolar pregnancy, and metastases outside the lungs [<a href="#rid65">65</a>].</p><p></p><p class="headingAnchor" id="H19650348"><span class="h2">Hepatic metastases</span><span class="headingEndMark"> — </span>Management of persistent liver metastases can be a particularly difficult and challenging problem. Hepatic resection or selective embolization may be used in select cases to control bleeding or excise resistant tumor [<a href="#rid70">70-72</a>]. Because of their hypervascular nature, biopsy should not be performed because of the potential for life-threatening hemorrhage. In a series from Charing Cross Hospital, after excluding early deaths, the cause-specific survival was 68 percent in patients with liver metastases [<a href="#rid73">73,74</a>].</p><p class="headingAnchor" id="H19650354"><span class="h2">Pulmonary metastases</span><span class="headingEndMark"> — </span>Resection of chemoresistant pulmonary disease can be curative. In one report of 15 patients with chemoresistant lung metastases, 14 achieved remission [<a href="#rid75">75</a>]. Positive prognostic indicators include normalization of hCG within one to two weeks after resection of a pulmonary metastasis [<a href="#rid76">76</a>], and a separate series reported that successful outcomes were possible even after multiple resections [<a href="#rid77">77</a>]. When evaluating patients for thoracotomy, it is important to remember that fibrotic lung nodules may mimic areas of active disease.</p><p>Criteria that predict favorable outcome include [<a href="#rid75">75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of other systemic metastases</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of a unilateral solitary nodule</p><p class="bulletIndent1"><span class="glyph">●</span>No uterine involvement</p><p class="bulletIndent1"><span class="glyph">●</span>Serum hCG &lt;1500 milli-international units/mL</p><p></p><p>Prior to surgery, other sites of metastases should be excluded. It is particularly important to determine that the nodule contains viable tumor, since nonviable fibrotic nodules may persist indefinitely after tumor regression [<a href="#rid66">66</a>]. One study suggested that a residual lung lesion on imaging after completion of GTN treatment was not associated with increased relapse rate [<a href="#rid14">14</a>]. Positron emission tomography combined with computerized tomography (PET/CT) scans have been used to identify viable tumor before surgery [<a href="#rid13">13,78</a>]. Since most resistant pulmonary nodules contain choriocarcinoma, it is not unusual for patients to require additional chemotherapy to treat occult disease. However, additional therapy may not be necessary if the hCG level declines promptly and remains undetectable during follow-up. Several investigators have reported that undetectable hCG levels one or two weeks after resection of a solitary nodule is highly predictive of a favorable outcome [<a href="#rid79">79-81</a>], and residual lung lesions after normalization of hCG levels do not alter the prognosis of GTN [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H19650360"><span class="h2">Brain metastases</span><span class="headingEndMark"> — </span>Craniotomy can play a vital role in the management of GTN cerebral metastases. It is indicated for the resection of peripheral, solitary, drug-resistant lesions and can be life-saving, especially in the context of a neurologic emergency due to intracranial hemorrhage or increased intracranial pressure [<a href="#rid83">83-85</a>]. Resection of intracranial disease can also result in a remission. This was shown in a series of patients who underwent craniotomy for drug-resistant disease [<a href="#rid86">86</a>]. Following craniotomy, five of seven patients had a complete remission. In addition to surgery, radiation, either stereotactic or whole brain, can be employed. Furthermore, the dose of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> in the setting of brain metastasis needs to be increased to 1 g/m<sup>2</sup>. In one series of 27 patients with brain metastases, 85 percent of patients were long-term survivors [<a href="#rid85">85</a>]. These patients received neurosurgery, when indicated, increased MTX dosing (1 g/m<sup>2</sup>), and intrathecal MTX (12.5 mg), but did not undergo any radiotherapy.</p><p class="headingAnchor" id="H539450272"><span class="h1">IS THERE A ROLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT?</span><span class="headingEndMark"> — </span>The use of high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HDSCT) is not clear, and the experience with this is mainly limited to case reports [<a href="#rid87">87-89</a>]. For example, in one study of 11 patients with previously treated disease, only two temporary complete responses were reported [<a href="#rid89">89</a>]. However, in an updated review, 32 patients were treated with HDSCT, and 7 patients achieved complete sustained remission and 6 additional patients attained remission with additional treatment [<a href="#rid90">90</a>]. Overall, 13 of 32 (41 percent) patients achieved complete remission after HDSCT. The patients that survived had human chorionic gonadotropin values ≤12 IU/L before HDSCT. Although encouraging, the role of HDSCT in GTN has not yet been clearly defined. However, the use of autologous hematopoietic stem cell transplant, which is associated with profound immunosuppression, should be avoided during the COVID-19 pandemic [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H2420909222"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120644.html" rel="external">"Society guideline links: Gestational trophoblastic disease"</a>.)</p><p class="headingAnchor" id="H853917093"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Prior to the development of effective chemotherapy for gestational trophoblastic neoplasia (GTN), metastatic disease was almost uniformly fatal. With the utilization of sensitive quantitative assays for human chorionic gonadotropin (hCG) and highly effective chemotherapy, patients with resistant disease and those who experience a recurrence stand a good chance of achieving remission. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients treated for GTN are at varying risks of developing either resistant or recurrent disease. In one study, the reported recurrence rates were 2, 4, and 13 percent for stage I (non-metastatic), stage II to III (low-risk), and stage III to IV (high-risk) disease. (See <a class="local">'Estimating the risk of resistant or recurrent disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who recur or develop resistance often have multiorgan involvement, particularly if they were previously treated for high-risk GTN. Therefore, re-imaging with chest, abdominal, and pelvic CT scans and brain MRI should be performed. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with low-risk GTN who are resistant to or recur after prior single-agent treatment, we recommend an alternative single agent rather than multiagent chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). For example, patients who are resistant to or recur after prior treatment with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) with or without folinic acid (FA) should receive biweekly bolus actinomycin D (ActD). (See <a class="local">'Second-line single-agent chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients previously diagnosed with low-risk GTN who develop resistant or recurrent disease despite two prior regimens using single agents, we administer combination chemotherapy. We suggest <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, MTX, ActD, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (EMA-CO) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Progression after second-line single-agent therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with high-risk GTN who have resistant or recurrent disease after first-line combination chemotherapy, our approach is as follows (see <a class="local">'Second-line combination therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients previously treated with EMA-CO, we suggest EMA followed by <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (EMA-EP) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See  <a class="medical medical_review" href="/d/html/96232.html" rel="external">"Initial management of high-risk gestational trophoblastic neoplasia", section on 'Cisplatin-containing regimens'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients not treated with EMA-CO in the first-line setting, we suggest EMA-CO (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who develop resistant or recurrent disease despite two lines of multiagent chemotherapy, alternative combination regimens are available. In the absence of prospective data, there is no one preferred regimen. It is important to re-stage patients prior to the initiation of a new regimen so that the extent of disease may be appropriately characterized and to evaluate for a potential role for surgical treatment. (See <a class="local">'Later-line therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with recurrent or resistant GTN, a surgical approach may be curative. However, decisions regarding surgery must be individualized based upon the clinical scenario. The efficacy, feasibility, and type of surgery vary depending upon the site and extent of metastases. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="headingAnchor" id="H2948417052"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Donald Peter Goldstein, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Freitas F, Braga A, Viggiano M, et al. Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol 2020; 158:452.</a></li><li><a class="nounderline abstract_t">Brewer JI, Eckman TR, Dolkart RE, et al. Gestational trophoblastic disease. A comparative study of the results of therapy in patients with invasive mole and with choriocarcinoma. Am J Obstet Gynecol 1971; 109:335.</a></li><li><a class="nounderline abstract_t">Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am 2012; 26:111.</a></li><li><a class="nounderline abstract_t">Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet 2021; 155 Suppl 1:86.</a></li><li><a class="nounderline abstract_t">Lurain JR, Hoekstra AV, Schink JC. Results of treatment of patients with gestational trophoblastic neoplasia referred to the Brewer Trophoblastic Disease Center after failure of treatment elsewhere (1979-2006). J Reprod Med 2008; 53:535.</a></li><li><a class="nounderline abstract_t">Mutch DG, Soper JT, Babcock CJ, et al. Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer 1990; 66:978.</a></li><li><a class="nounderline abstract_t">Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112:654.</a></li><li><a class="nounderline abstract_t">Kong Y, Zong L, Cheng H, et al. Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017. Cancer Med 2020; 9:2590.</a></li><li><a class="nounderline abstract_t">Eysbouts YK, Ottevanger PB, Massuger LFAG, et al. Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset. Ann Oncol 2017; 28:1856.</a></li><li><a class="nounderline abstract_t">Agarwal R, Harding V, Short D, et al. Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia. Br J Cancer 2012; 106:1089.</a></li><li><a class="nounderline abstract_t">Asmar FTC, Braga-Neto AR, de Rezende-Filho J, et al. Uterine artery Doppler flow velocimetry parameters for predicting gestational trophoblastic neoplasia after complete hydatidiform mole, a prospective cohort study. Clinics (Sao Paulo) 2017; 72:284.</a></li><li><a class="nounderline abstract_t">Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer 2007; 96:732.</a></li><li><a class="nounderline abstract_t">Yang J, Xiang Y, Wan X, Yang X. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol 2006; 103:479.</a></li><li><a class="nounderline abstract_t">Bouchard-Fortier G, Ghorani E, Short D, et al. Following chemotherapy for gestational trophoblastic neoplasia, do residual lung lesions increase the risk of relapse? Gynecol Oncol 2020; 158:698.</a></li><li><a class="nounderline abstract_t">Dhillon T, Palmieri C, Sebire NJ, et al. Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med 2006; 51:879.</a></li><li><a class="nounderline abstract_t">Chapman-Davis E, Hoekstra AV, Rademaker AW, et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol 2012; 125:572.</a></li><li><a class="nounderline abstract_t">Maestá I, Nitecki R, Horowitz NS, et al. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol 2018; 148:161.</a></li><li><a class="nounderline abstract_t">Cortés-Charry R, Hennah L, Froeling FEM, et al. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy. ESMO Open 2021; 6:100110.</a></li><li><a class="nounderline abstract_t">McGrath S, Short D, Harvey R, et al. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer 2010; 102:810.</a></li><li><a class="nounderline abstract_t">Braga A, Paiva G, Ghorani E, et al. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol 2021; 22:1188.</a></li><li><a class="nounderline abstract_t">Maestá I, Nitecki R, Desmarais CCF, et al. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2020; 157:372.</a></li><li><a class="nounderline abstract_t">Prouvot C, Golfier F, Massardier J, et al. Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia. Int J Gynecol Cancer 2018; 28:1038.</a></li><li><a class="nounderline abstract_t">Jareemit N, Horowitz NS, Goldstein DP, et al. Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. Gynecol Oncol 2020; 159:751.</a></li><li><a class="nounderline abstract_t">Mora PAR, Sun SY, Velarde GC, et al. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol 2019; 153:277.</a></li><li><a class="nounderline abstract_t">Winter MC, Tidy JA, Hills A, et al. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2016; 143:565.</a></li><li><a class="nounderline abstract_t">You B, Bolze PA, Lotz JP, et al. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. J Clin Oncol 2020; 38:3129.</a></li><li><a class="nounderline abstract_t">Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score &gt; or = 7. J Reprod Med 2010; 55:199.</a></li><li><a class="nounderline abstract_t">Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 2005; 97:618.</a></li><li><a class="nounderline abstract_t">Ngan HY, Tam KF, Lam KW, Chan KK. Relapsed gestational trophoblastic neoplasia: A 20-year experience. J Reprod Med 2006; 51:829.</a></li><li><a class="nounderline abstract_t">Kanis MJ, Greendyk RA, Sobecki-Rausch J, et al. Use of granulocyte colony-stimulating factors with multiagent chemotherapy for high-risk gestational trophoblastic neoplasia decreases neutropenic complications and treatment delays. J Reprod Med 2018; 63:209.</a></li><li><a class="nounderline abstract_t">Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000; 18:854.</a></li><li><a class="nounderline abstract_t">Mao Y, Wan X, Lv W, Xie X. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. Int J Gynaecol Obstet 2007; 98:44.</a></li><li><a class="nounderline abstract_t">Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2012; 57:219.</a></li><li><a class="nounderline abstract_t">Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997; 15:2636.</a></li><li><a class="nounderline abstract_t">Osborne R, Covens A, Mirchandani D, Gerulath A. Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet. J Reprod Med 2004; 49:655.</a></li><li><a class="nounderline abstract_t">Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol 2008; 19:1578.</a></li><li><a class="nounderline abstract_t">Rustin GJ, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996; 14:2769.</a></li><li><a class="nounderline abstract_t">Savage P, Cooke R, O'Nions J, et al. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol 2015; 33:472.</a></li><li><a class="nounderline abstract_t">Rathod PS, Kundargi R, Pallavi VR, et al. Refractory Gestational Trophoblastic Neoplasia: A Novel Drug Combination With Paclitaxel and Carboplatin Produces Durable Complete Remission. Int J Gynecol Cancer 2015; 25:1737.</a></li><li><a class="nounderline abstract_t">Gordon AN, Kavanagh JJ, Gershenson DM, et al. Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease. Cancer 1986; 58:1407.</a></li><li><a class="nounderline abstract_t">DuBeshter B, Berkowitz RS, Goldstein DP, Bernstein M. Vinblastine, cisplatin and bleomycin as salvage therapy for refractory high-risk metastatic gestational trophoblastic disease. J Reprod Med 1989; 34:189.</a></li><li><a class="nounderline abstract_t">Azab M, Droz JP, Theodore C, et al. Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors. Cancer 1989; 64:1829.</a></li><li><a class="nounderline abstract_t">Matsui H, Suzuka K, Iitsuka Y, et al. Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors. Cancer 2002; 95:1051.</a></li><li><a class="nounderline abstract_t">Wan X, Yang X, Xiang Y, et al. Floxuridine-containing regimens in the treatment of gestational trophoblastic tumor. J Reprod Med 2004; 49:453.</a></li><li><a class="nounderline abstract_t">Horowitz NS, Goldstein DP, Berkowitz RS. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. Gynecol Oncol 2017; 144:208.</a></li><li><a class="nounderline abstract_t">Zhao J, Lv WG, Feng FZ, et al. Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment. Gynecol Oncol 2016; 142:102.</a></li><li><a class="nounderline abstract_t">Feng F, Xiang Y, Wan X, et al. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. Ann Oncol 2011; 22:1588.</a></li><li><a class="nounderline abstract_t">Termrungruanglert W, Kudelka AP, Piamsomboon S, et al. Remission of refractory gestational trophoblastic disease with high-dose paclitaxel. Anticancer Drugs 1996; 7:503.</a></li><li><a class="nounderline abstract_t">Jones WB, Schneider J, Shapiro F, Lewis JL Jr. Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases. Gynecol Oncol 1996; 61:126.</a></li><li><a class="nounderline abstract_t">Bianconi M, Jankilevich G, Otero S, et al. Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine. Gynecol Oncol 2007; 106:268.</a></li><li><a class="nounderline abstract_t">Popadiuk C, Power P. Pegylated Liposomal Doxorubicin Is an Active Agent for Chemotherapy-Resistant Choriocarcinoma: A Report of Two Cases. J Reprod Med 2016; 61:215.</a></li><li><a class="nounderline abstract_t">Bolze PA, Patrier S, Massardier J, et al. PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes. Int J Gynecol Cancer 2017; 27:554.</a></li><li><a class="nounderline abstract_t">Veras E, Kurman RJ, Wang TL, Shih IM. PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. Int J Gynecol Pathol 2017; 36:146.</a></li><li><a class="nounderline abstract_t">Inaguma S, Wang Z, Lasota J, et al. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors. Am J Surg Pathol 2016; 40:1133.</a></li><li><a class="nounderline abstract_t">Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet 2017; 390:2343.</a></li><li><a class="nounderline abstract_t">Clair KH, Gallegos N, Bristow RE. Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors. Gynecol Oncol Rep 2020; 34:100625.</a></li><li><a class="nounderline abstract_t">Goldfarb JA, Dinoi G, Mariani A, Langstraat CL. A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab. Gynecol Oncol Rep 2020; 32:100574.</a></li><li><a class="nounderline abstract_t">Worley MJ Jr, Elias KM, Horowitz NS, et al. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol 2018; 148:5.</a></li><li><a class="nounderline abstract_t">Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. J Reprod Med 2012; 57:231.</a></li><li><a class="nounderline abstract_t">Cagayan MS, Magallanes MS. The role of adjuvant surgery in the management of gestational trophoblastic neoplasia. J Reprod Med 2008; 53:513.</a></li><li><a class="nounderline abstract_t">Eysbouts YK, Massuger LFAG, IntHout J, et al. The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecol Oncol 2017; 145:536.</a></li><li><a class="nounderline abstract_t">Clark RM, Nevadunsky NS, Ghosh S, et al. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2010; 55:194.</a></li><li><a class="nounderline abstract_t">Fülöp V, Szigetvári I, Szepesi J, et al. The Role of Surgery in the Management of Gestational Trophoblastic Neoplasia The Hungarian Experience. J Reprod Med 2016; 61:197.</a></li><li><a class="nounderline abstract_t">Sugrue R, Foley O, Elias KM, et al. Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease. Gynecol Oncol 2021; 160:445.</a></li><li><a class="nounderline abstract_t">Soper JT. Identification and management of high-risk gestational trophoblastic disease. Semin Oncol 1995; 22:172.</a></li><li><a class="nounderline abstract_t">Soper JT. Surgical therapy for gestational trophoblastic disease. J Reprod Med 1994; 39:168.</a></li><li><a class="nounderline abstract_t">Soper JT. Role of surgery and radiation therapy in the management of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2003; 17:943.</a></li><li><a class="nounderline abstract_t">Feng F, Xiang Y, Li L, et al. Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia. Gynecol Oncol 2009; 113:312.</a></li><li><a class="nounderline abstract_t">Lehman E, Gershenson DM, Burke TW, et al. Salvage surgery for chemorefractory gestational trophoblastic disease. J Clin Oncol 1994; 12:2737.</a></li><li><a class="nounderline abstract_t">Wong LC, Choo YC, Ma HK. Hepatic metastases in gestational trophoblastic disease. Obstet Gynecol 1986; 67:107.</a></li><li><a class="nounderline abstract_t">Grumbine FC, Rosenshein NB, Brereton HD, Kaufman SL. Management of liver metastasis from gestational trophoblastic neoplasia. Am J Obstet Gynecol 1980; 137:959.</a></li><li><a class="nounderline abstract_t">Lok CA, Reekers JA, Westermann AM, Van der Velden J. Embolization for hemorrhage of liver metastases from choriocarcinoma. Gynecol Oncol 2005; 98:506.</a></li><li><a class="nounderline abstract_t">Crawford RA, Newlands E, Rustin GJ, et al. Gestational trophoblastic disease with liver metastases: the Charing Cross experience. Br J Obstet Gynaecol 1997; 104:105.</a></li><li><a class="nounderline abstract_t">Ahamed E, Short D, North B, et al. Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving? J Reprod Med 2012; 57:262.</a></li><li><a class="nounderline abstract_t">Tomoda Y, Arii Y, Kaseki S, et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer 1980; 46:2723.</a></li><li><a class="nounderline abstract_t">Fleming EL, Garrett L, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2008; 53:493.</a></li><li><a class="nounderline abstract_t">Alifrangis C, Wilkinson MJ, Stefanou DC, et al. Role of thoracotomy and metastatectomy in gestational trophoblastic neoplasia: a single center experience. J Reprod Med 2012; 57:350.</a></li><li><a class="nounderline abstract_t">Mapelli P, Mangili G, Picchio M, et al. Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. Eur J Nucl Med Mol Imaging 2013; 40:505.</a></li><li><a class="nounderline abstract_t">Edwards JL, Makey AR, Bagshawe KD. The role of thoracotomy in the management of the pulmonary metastases of gestational choriocarcinoma. Clin Oncol 1975; 1:329.</a></li><li><a class="nounderline abstract_t">Sink JD, Hammond CB, Young WG Jr. Pulmonary resection in the management of metastases from gestational choriocarcinoma. J Thorac Cardiovasc Surg 1981; 81:830.</a></li><li><a class="nounderline abstract_t">Wang YA, Song HZ, Xia ZF, Sun CF. Drug resistant pulmonary choriocarcinoma metastasis treated by lobectomy: report of 29 cases. Chin Med J (Engl) 1980; 93:758.</a></li><li><a class="nounderline abstract_t">Li X, Yang B, Chen J, et al. Do the Residual Lung Lesions Threaten Gestational Trophoblastic Neoplasia Patients? Int J Gynecol Cancer 2018; 28:1410.</a></li><li><a class="nounderline abstract_t">Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 2002; 47:465.</a></li><li><a class="nounderline abstract_t">Neubauer NL, Latif N, Kalakota K, et al. Brain metastasis in gestational trophoblastic neoplasia: an update. J Reprod Med 2012; 57:288.</a></li><li><a class="nounderline abstract_t">Savage P, Kelpanides I, Tuthill M, et al. Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol 2015; 137:73.</a></li><li><a class="nounderline abstract_t">Evans AC Jr, Soper JT, Clarke-Pearson DL, et al. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 1995; 59:226.</a></li><li><a class="nounderline abstract_t">van Besien K, Verschraegen C, Mehra R, et al. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol 1997; 65:366.</a></li><li><a class="nounderline abstract_t">Giacalone PL, Benos P, Donnadio D, Laffargue F. High-dose chemotherapy with autologous bone marrow transplantation for refractory metastatic gestational trophoblastic disease. Gynecol Oncol 1995; 58:383.</a></li><li><a class="nounderline abstract_t">El-Helw LM, Seckl MJ, Haynes R, et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. Br J Cancer 2005; 93:620.</a></li><li><a class="nounderline abstract_t">Frijstein MM, Lok CAR, Short D, et al. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. Eur J Cancer 2019; 109:162.</a></li><li><a class="nounderline abstract_t">Braga A, Elias KM, Elias KM, et al. How to optimize the management of gestational trophoblastic disease during the coronavirus disease era? Am J Obstet Gynecol 2020; 223:604.</a></li></ol></div><div id="topicVersionRevision">Topic 96235 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32402634" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5539127" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gestational trophoblastic disease. A comparative study of the results of therapy in patients with invasive mole and with choriocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22244665" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Current management of gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34669197" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and management of gestational trophoblastic disease: 2021 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720930" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Results of treatment of patients with gestational trophoblastic neoplasia referred to the Brewer Trophoblastic Disease Center after failure of treatment elsewhere (1979-2006).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2167150" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18851873" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Current management of gestational trophoblastic diseases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32022487" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28459944" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22374461" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591340" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Uterine artery Doppler flow velocimetry parameters for predicting gestational trophoblastic neoplasia after complete hydatidiform mole, a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299394" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16631244" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654764" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Following chemotherapy for gestational trophoblastic neoplasia, do residual lung lesions increase the risk of relapse?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17165434" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22449733" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29092742" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33845362" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increasing the human chorionic gonadotrophin cut-off to≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20160727" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34181884" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32037196" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29629964" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33023756" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30857648" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27756557" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32716740" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20626175" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score&gt;or = 7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863169" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17086812" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Relapsed gestational trophoblastic neoplasia: A 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of granulocyte colony-stimulating factors with multiagent chemotherapy for high-risk gestational trophoblastic neoplasia decreases neutropenic complications and treatment delays</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673528" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17481633" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696816" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215835" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15457856" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18453518" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874338" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25547507" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26401644" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Refractory Gestational Trophoblastic Neoplasia: A Novel Drug Combination With Paclitaxel and Carboplatin Produces Durable Complete Remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2427185" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2470902" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Vinblastine, cisplatin and bleomycin as salvage therapy for refractory high-risk metastatic gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2477136" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209690" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15283053" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Floxuridine-containing regimens in the treatment of gestational trophoblastic tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789086" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27168005" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239399" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862714" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Remission of refractory gestational trophoblastic disease with high-dose paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626100" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493670" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27424361" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pegylated Liposomal Doxorubicin Is an Active Agent for Chemotherapy-Resistant Choriocarcinoma: A Report of Two Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28060141" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27362903" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27158757" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29185430" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32964090" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32395603" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217138" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696818" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720926" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The role of adjuvant surgery in the management of gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28390821" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The added value of hysterectomy in the management of gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20626174" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27424358" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The Role of Surgery in the Management of Gestational Trophoblastic Neoplasia The Hungarian Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33272644" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7740319" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Identification and management of high-risk gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035372" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Surgical therapy for gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14614891" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Role of surgery and radiation therapy in the management of gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19345988" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7989951" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Salvage surgery for chemorefractory gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2999663" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hepatic metastases in gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6250404" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Management of liver metastasis from gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15979698" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Embolization for hemorrhage of liver metastases from choriocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988707" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Gestational trophoblastic disease with liver metastases: the Charing Cross experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696824" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7192596" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Surgical indications for resection in pulmonary metastasis of choriocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720924" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22838253" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Role of thoracotomy and metastatectomy in gestational trophoblastic neoplasia: a single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23314259" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1212836" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The role of thoracotomy in the management of the pulmonary metastases of gestational choriocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7194950" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pulmonary resection in the management of metastases from gestational choriocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6775886" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Drug resistant pulmonary choriocarcinoma metastasis treated by lobectomy: report of 29 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30142125" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Do the Residual Lung Lesions Threaten Gestational Trophoblastic Neoplasia Patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12092015" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Management of brain metastases in patients with high-risk gestational trophoblastic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22838242" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Brain metastasis in gestational trophoblastic neoplasia: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25598530" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7590478" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Gestational trophoblastic disease metastatic to the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9159354" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7672706" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : High-dose chemotherapy with autologous bone marrow transplantation for refractory metastatic gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16222307" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30731277" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32474011" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : How to optimize the management of gestational trophoblastic disease during the coronavirus disease era?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
